 Cowen Co initiated coverage on Molecular Partners NASDAQ: MOLN with an Outperform rating and a Price Target of 50, implying an upside potential of more than 150. The company and its partner Novartis AG NYSE: NVS recently shared preclinical data showing that ensovibep retains full potency and viral inhibition against all known COVID-19 variants in circulation, including the key Delta variants. 